Option Care Health

Option Care Health

Largest independent home infusion therapy provider

About Option Care Health

Simplify's Rating
Why Option Care Health is rated
C+
Rated B on Competitive Edge
Rated C on Growth Potential
Rated C on Differentiation

Industries

Consulting

Enterprise Software

AI & Machine Learning

Healthcare

Biotechnology

Data & Analytics

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Norfolk, Virginia

Founded

1979

Overview

Option Care Health delivers infusion therapies at home and other alternate-site locations across the United States, supported by over 7,000 teammates including about 4,500 clinicians. Clinicians visit patients at home or approved sites to administer therapies, manage care, and coordinate with care teams under strong clinical leadership and national scale. It stands out as the largest independent infusion provider with nationwide reach and a robust clinical workforce, enabling scalable home and alternate-site infusion rather than hospital-only care. The goal is to elevate standards of care and reimagine the infusion care experience by expanding access, improving outcomes, and delivering compassionate, clinically driven service.

Simplify Jobs

Simplify's Take

What believers are saying

  • Analyst price targets up to $40.09 suggest 46% upside from May levels.
  • Expanded $850M credit facility enables M&A consolidation in fragmented market.
  • Management projects $7B revenue by 2029 assuming CID reset normalizes.

What critics are saying

  • Chronic Inflammatory Disease portfolio headwind of $55M persists beyond 2026.
  • Revenue growth slowed to 1.1% versus historical 12% and industry 4.7%.
  • Biosimilar conversions and IRA headwinds compress margins $25–35M annually through 2027.

What makes Option Care Health unique

  • Largest independent home infusion provider with 315,000+ unique patients served.
  • 40% of claims processed without human intervention via automation investments.
  • Diversified portfolio across acute, chronic, and immunoglobulin neurology therapies.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1.7B

Above

Industry Average

Funded Over

4 Rounds

Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Debt Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Time Off

Bonding Time Off

401(k) Retirement Plan

401(k) Company Match

Health Savings Account/Flexible Spending Account

Flexible Spending Accounts

Tuition Reimbursement

Family Support

Mental Health Support

Company Paid Life Insurance

Award/Recognition Programs

Stock Price

Company News

Simply Wall St
Apr 4th, 2026
Option Care Health expands credit facility to $850M, boosts buyback to $1B

Option Care Health has expanded its revolving credit facility by $450 million to $850 million and increased its share repurchase authorisation to $1 billion, whilst reaffirming its 2026 guidance. The moves strengthen liquidity and signal management confidence in cash generation. The expanded buyback and credit facility provide greater flexibility for growth investments and capital returns, though near-term focus remains on executing guidance and managing reimbursement pressures. The company's narrative projects $7 billion revenue and $302.2 million earnings by 2029, implying 7.5% annual revenue growth. Analyst fair value estimates range widely from $3.66 to $40.09 per share, with the upper estimate suggesting 46% upside from current prices.

MicroCare
Mar 9th, 2026
MicroCare Medical welcomes Matt Lingenfelter as national sales manager, healthcare.

MicroCare Medical welcomes Matt Lingenfelter as national sales manager, healthcare. March 09, 2026 MicroCare Medical is pleased to welcome Matt Lingenfelter as national sales manager, healthcare. With more than 20 years of experience in healthcare sales and leadership, Matt will help drive national growth and strengthen partnerships for the MicroCare Medical instrument care and infection prevention solutions. In this role, Matt will guide healthcare sales strategy across the U.S., focusing on expanding key accounts, building strong distributor relationships, and supporting the sales team. He will also work closely with marketing, operations, and product development to ensure MicroCare continues delivering solutions that meet the evolving needs of healthcare professionals. Before joining MicroCare, Matt held leadership roles with Option Care Health, Belimed, and Aesculap, where he developed deep expertise in surgical instrumentation, endoscopic technologies, and hospital system support. "Matt's experience and understanding of healthcare systems make him a fantastic addition to our team," said Ray Bellavance, vice president of global sales and marketing at MicroCare. "We're excited to have him help grow our healthcare business and strengthen partnerships across the country."

Yahoo Finance
Feb 27th, 2026
Option Care Health posts 13% revenue growth despite $25M–35M Stelara biosimilar headwind

Option Care Health reported a 13% revenue increase in Q4 2025, with acute therapies growing in the mid-teens and chronic therapies in the low double digits. The company served over 315,000 unique patients and improved operational efficiency, with 40% of claims now processed without human intervention. For 2026, the company issued revenue guidance of $5.8 billion to $6 billion, incorporating a 400 basis point headwind from Stelara biosimilar conversions and Inflation Reduction Act impacts. Adjusted EBITDA is projected at $480 million to $505 million, accounting for a $25 million to $35 million gross profit headwind from Stelara transitions. Operating cash flow is expected to exceed $340 million, representing over 30% growth. The company plans to launch at least two new pharmaceutical manufacturer programmes and expand its infusion clinic model to support higher-acuity therapies.

PREEMPT, Inc
Sep 30th, 2025
EEOC Sues Option Care Health, Inc. for Pregnancy Discrimination

EEOC sues Option Care Health, Inc. for pregnancy discrimination.

Option Care Health
Aug 7th, 2025
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

Quince Therapeutics selects Option Care Health as specialty infusion therapy provider for administration of lead asset eDSP.

Recently Posted Jobs

Sign up to get curated job recommendations

Option Care Health is Hiring for 262 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →